Cartesian CEO Sells Shares in Routine Tax Move as Stock Surges 20% This Week
Insider sales at Cartesian Therapeutics are routine, not a red flag—executives trade vested RSUs while the company’s 20% weekly rally and 30% net‑long ownership signal confidence in future RNA‑cell breakthroughs.
3 minutes to read